Cytori Therapeutics Inc (CYTX) Short Interest Up 59.9% in October
Cytori Therapeutics Inc (NASDAQ:CYTX) saw a large increase in short interest in October. As of October 13th, there was short interest totalling 2,479,206 shares, an increase of 59.9% from the September 29th total of 1,550,524 shares. Approximately 7.5% of the company’s stock are sold short. Based on an average daily trading volume, of 3,242,076 shares, the days-to-cover ratio is currently 0.8 days.
CYTX has been the topic of a number of research reports. ValuEngine upgraded shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 13th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Tuesday, July 11th. B. Riley lowered shares of Cytori Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, July 25th. Finally, Maxim Group set a $10.00 target price on shares of Cytori Therapeutics and gave the stock a “buy” rating in a report on Monday, July 10th.
Shares of Cytori Therapeutics (NASDAQ CYTX) opened at 0.4301 on Friday. The firm’s market capitalization is $14.93 million. The firm’s 50-day moving average is $0.42 and its 200-day moving average is $0.74. Cytori Therapeutics has a 12-month low of $0.28 and a 12-month high of $2.13.
Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The business had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.23 million. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. Cytori Therapeutics’s quarterly revenue was down 18.2% compared to the same quarter last year. Equities research analysts forecast that Cytori Therapeutics will post ($0.60) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of CYTX. Perkins Capital Management Inc. lifted its position in shares of Cytori Therapeutics by 99.0% during the second quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock worth $962,000 after purchasing an additional 435,217 shares in the last quarter. Sabby Management LLC lifted its position in shares of Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 355,504 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Cytori Therapeutics by 81.9% during the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after purchasing an additional 275,653 shares in the last quarter. 11.84% of the stock is currently owned by institutional investors and hedge funds.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.